DNLI
Price
$15.42
Change
+$0.22 (+1.45%)
Updated
Oct 3 closing price
Capitalization
2.25B
24 days until earnings call
STOK
Price
$25.56
Change
+$0.74 (+2.98%)
Updated
Oct 3 closing price
Capitalization
1.4B
36 days until earnings call
Interact to see
Advertisement

DNLI vs STOK

Header iconDNLI vs STOK Comparison
Open Charts DNLI vs STOKBanner chart's image
Denali Therapeutics
Price$15.42
Change+$0.22 (+1.45%)
Volume$1.42M
Capitalization2.25B
Stoke Therapeutics
Price$25.56
Change+$0.74 (+2.98%)
Volume$749.89K
Capitalization1.4B
DNLI vs STOK Comparison Chart in %
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. STOK commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and STOK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (DNLI: $15.42 vs. STOK: $25.56)
Brand notoriety: DNLI and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 69% vs. STOK: 78%
Market capitalization -- DNLI: $2.25B vs. STOK: $1.4B
DNLI [@Biotechnology] is valued at $2.25B. STOK’s [@Biotechnology] market capitalization is $1.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 5 bearish.
  • STOK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than STOK.

Price Growth

DNLI (@Biotechnology) experienced а +10.54% price change this week, while STOK (@Biotechnology) price change was +5.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

STOK is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.26B) has a higher market cap than STOK($1.4B). STOK YTD gains are higher at: 131.732 vs. DNLI (-24.338). STOK has higher annual earnings (EBITDA): 42.3M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. STOK (248M). STOK has less debt than DNLI: STOK (2.3M) vs DNLI (46.6M). STOK has higher revenues than DNLI: STOK (200M) vs DNLI (0).
DNLISTOKDNLI / STOK
Capitalization2.26B1.4B161%
EBITDA-521.52M42.3M-1,233%
Gain YTD-24.338131.732-18%
P/E RatioN/A28.53-
Revenue0200M-
Total Cash899M248M363%
Total Debt46.6M2.3M2,030%
FUNDAMENTALS RATINGS
DNLI vs STOK: Fundamental Ratings
DNLI
STOK
OUTLOOK RATING
1..100
2830
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9746
PRICE GROWTH RATING
1..100
5735
P/E GROWTH RATING
1..100
1007
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (74) in the null industry is in the same range as DNLI (93) in the Biotechnology industry. This means that STOK’s stock grew similarly to DNLI’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to DNLI’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for DNLI (97) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than DNLI’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is in the same range as DNLI (57) in the Biotechnology industry. This means that STOK’s stock grew similarly to DNLI’s over the last 12 months.

STOK's P/E Growth Rating (7) in the null industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLISTOK
RSI
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 21 days ago
81%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRVIX36.630.23
+0.63%
Heartland Value Plus Investor
PURZX21.050.05
+0.24%
PGIM Global Real Estate Z
VYRDX13.910.02
+0.14%
VY® Columbia Small Cap Value II R6
CHCYX13.910.01
+0.07%
AB Discovery Growth Advisor
COFRX41.95N/A
N/A
Columbia Contrarian Core Inst2

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with QTTB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+2.98%
QTTB - STOK
49%
Loosely correlated
N/A
DNLI - STOK
48%
Loosely correlated
+1.45%
SYRE - STOK
47%
Loosely correlated
-0.56%
IDYA - STOK
46%
Loosely correlated
+1.62%
IMNM - STOK
46%
Loosely correlated
+7.93%
More